Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.

Genome medicine - 27 Jun 2026

Sokirniy Ivan, Yang Zeyu, Pritchard Justin

Abstract excerpt

BACKGROUND: Drug resistance is a constantly evolving challenge. The allosteric inhibitor asciminib is a novel therapy for chronic myelogenous leukemia (CML) that targets the myristoyl pocket of the BCR::ABL1 kinase. While it can overcome resistance to active-site inhibitors like imatinib, new resistance mutations to asciminib are emerging. The complete landscape of these mutations, particularly those outside the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Epistasis, Genetic
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Niacinamide

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 42365381
DOI: 10.1186/s13073-026-01679-x
PMCID: PMC13422289

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.PMID 42365381Read ↗

Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.Semantic proximity Read ↗

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibSemantic proximity Read ↗

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read ↗

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.Semantic proximity Read ↗

A novel hyperactive <i>BCR::ABL1</i> <sup> <i>e6a3</i> </sup> variant confers resistance to combined asciminib plus ponatinib therapySemantic proximity Read ↗

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.Semantic proximity Read ↗

Asciminib, a novel allosteric inhibitor of BCR‐ABL1 , shows synergistic effects when used in combination with imatinib with or without drug resistanceSemantic proximity Read ↗

Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinaseSemantic proximity Read ↗

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceSemantic proximity Read ↗

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read ↗

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.